Anti-Seizure Medications Alter the Brain's Network Topology

Mangor Pedersen[1], Heath R. Pardoe[2], Remika Mito[2], Moksh Sethi [3,4],
David N. Vaughan[2,5], Patrick W. Carney[3,6] & Graeme D. Jackson [2,5,7]

1. Department of Psychology and Neuroscience, Auckland University of Technology (AUT), Auckland, New Zealand
2. The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Australia.
3. Neurology Department, Eastern Health, Box Hill, Victoria, Australia
4. Neurology Department, Northern Health, Epping, Victoria, Australia
5. Department of Neurology, Austin Health, Melbourne, Australia.
6. Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia
7. Department of Medicine, Austin Health, The University of Melbourne, Australia

Abstract

Objectives: After a first epileptic seizure, anti-seizure medications (ASM) change the likelihood of having a further event. This prospective study aimed to quantify the brain network changes associated with the administration of ASM monotherapy.

Methods: We applied graph theoretical network analysis to longitudinal resting-state functional MRI (fMRI) data from 28 participants who had recently experienced their first seizure. Participants were imaged before and after ASM administration (on average, ~7 months between scans).

Results: After commencing ASM, we observed an increase in the clustering coefficient and a decrease in path length, suggesting a normalisation of brain networks. Individually, increased network small-worldness was observed in 75% (21/28) of subjects. Brain changes after ASM treatment were most prominent in superior frontoparietal and inferior frontal and temporal regions, associated with cognitive functions such as working memory and language.

Discussion: This proof-of-principle study suggests that ASM may normalize brain networks and could be a starting point for developing objective imaging markers for monitoring ASM response. Larger studies are required to understand further the connection between ASM-related brain network changes and long-term seizure status and epilepsy diagnosis.

Keywords: Anti-seizure medication, ASM, fMRI, networks, seizures.

Introduction

Anti-seizure medications (ASM) employ a variety of physiological mechanisms to decrease the frequency or intensity of seizures. Structural and functional MRI studies have shown brain changes associated with ASM treatment. For example, sodium valproate use is related to transient reductions in brain volume and cortical thickness in parietal and occipital cortices [1]. fMRI studies have shown that ASM can increase task-based brain activation, particularly in association cortices[2,3]. The fact that ASM reduce or eliminate abnormal electrographic activity that manifests as seizures in 2/3 of individuals with epilepsy suggests that they profoundly impact large-scale brain networks. Further understanding how medications affect brain network function may be essential to understanding why approximately one-third of epilepsy patients do not respond to ASM [4].

Brain networks are complex systems of interconnected brain regions that work together to perform specific functions, such as sensory action, language and other higher-order cognitive functions. Brain network function can be quantified in humans with EEG or fMRI. Brain networks are thought to be disrupted in epilepsy, which may contribute to developing seizures and the co-morbidities of epilepsy [5].

This study used advanced fMRI data collected after the first seizure and before ASM started. (pre-ASM) and after the start of ASM treatment (post-ASM) before applying graph theoretical metrics to quantify network organisation between the fMRI scans. Given the lack of prospective longitudinal studies on neuroimaging-based changes before and after commencing ASM, we conducted a whole-brain analysis of brain network changes after ASM administration.

Methods:

Study cohort

We recruited 37 participants after attending the first seizure clinics in Melbourne, Australia. 9 patients did not participate in the follow-up MRI scan and were excluded from the study. The final cohort, therefore, consisted of 28 participants studied across two time-points. The Austin Health Human Research Ethics Committee, Melbourne, Australia, approved this study, and subjects gave written consent to participate. The cohort had a mean age of 32+/-13 years, with 15 female and 13 male participants. The mean inter-scan interval was 6.9+/-2.5 months. At the second scan, participants were taking a variety of ASM: Lamotrigine (14/28); Carbamazepine (6/28); Levetiracetam (4/28); Valproic Acid (3/28), Topiramate (1/28). Long-term clinical outcome of seizure control and epilepsy diagnosis was not included in the analysis due to the small sample size in our proof of principle study. See further cohort information in Supplementary Materials 1.

fMRI network analysis

After preprocessing the data with *fmriprep* [6] (full details in Supplementary Materials 2), we parcellated the fMRI data using a Glasser parcellation mask with 180 symmetric brain regions (nodes) [7]. Pearson *r* correlation was used to estimate functional connectivity between all nodes. We computed binary and proportionally thresholded networks between 20%-60% network density (i.e., the percentage of connections retained in the networks) with 5% increments using the Brain Connectivity Toolbox (https://sites.google.com/site/bctnet/).

Graph theoretical measures used in this study included *clustering coefficient, path length betweenness centrality* and *normalized participation coefficient*. The *clustering coefficient* measures the number of interconnected local triangular nodes [8]. The clustering coefficient, therefore, reflects the local segregation or clustering of nodes in a network. The *path length* of a network is estimated as the shortest possible path that connects two nodes [8]. The path length is a measure of network efficiency. We also calculated network small-worldness as the fraction between the normalised clustering coefficient and normalised path length. The *betweenness centrality* measures brain hubs, reflecting the node's importance in the network by calculating the shortest paths that pass through a node, normalised to have values between 0 and 1. The normalised *participation coefficient* measures whether a node connects to its module or other modules and counters potential systematic effects between module size and node participation [9].

Statistical analysis
The average of all network densities was used for statistical analysis. Within-subject paired-sample t-tests were used for statistical analysis. False discovery rate (FDR) was used to correct for multiple comparisons.

Results
Whole-brain averaged results
After administering ASM, we found an increase in clustering coefficient ($t(27) = 2.63$, $p = 0.02$) and a decrease in path length ($t(27) = -2.94$, $p = 0.01$), averaged over all nodes. There was no difference between pre-ASM and post-ASM for betweenness centrality ($t(27) = 0.62$, $p = 0.54$) and participation coefficient ($t(27) = 1.31$, $p = 0.20$). Results were FDR corrected, $p < 0.05$ (Figure 1). The clustering coefficient and path length are similar across subjects, whereas the participation coefficient is a distinct graph metric (Supplementary Materials 3).

Figure 1: *Network topology results averaged over all brain nodes. Blue lines = pre-ASM; Red lines = post-ASM. The shaded error in the top row is the standard error. On the bottom row, we display the distribution.*

Region-specific results and behavioural meta-analysis
We also found that ASM administration resulted in changes in specific brain regions, including the superior frontal cortex (increased clustering coefficient and betweenness centrality as well as decreased path length, postASM – yellow nodes in Figure 2) as well as the anterior insula and superior temporal gyrus (increased clustering coefficient and reduced path length, post-ASM – red nodes in Figure 2). We also observed increased betweenness centrality post-ASM in the inferior parietal lobe and inferior frontal cortex – black nodes in Figure 2. All nodal results were FDR corrected, $p < 0.05$.

Using a meta-analytic approach in neurosynth.org, we found that working memory (frontoparietal areas) and language/tasks (inferior frontal and temporal areas) were the most strongly associated with significant brain regions in Figure 2 (see Supplementary Materials 4).

Figure 2: *Statistically significant nodes between pre-ASM and post-ASM. Yellow nodes = 3 significant graph theory metrics (clustering coefficient, path length and betweenness centrality). Red nodes = 2 significant graph theory metrics (clustering coefficient and path length). Black nodes = 1 significant graph theory metric (betweenness centrality).*

There is no network difference between Lamotrigine and other ASM
Next, we conducted a subgroup analysis between people on Lamotrigine (N=14) and other ASM (N=14). We observed no significant difference between Lamotrigine and other ASM on a whole-brain averaged and region-specific level in our four network metrics.

Individual brain network changes after commencing ASM treatment
After investigating the network effects of ASM on a group level, we were interested in exploring network-specific changes in individuals. We observed that 21/28 (75%) participants had network patterns with an increasingly small-world topology after the onset of ASM (Figure 3). See also functional connectivity similarity between individuals in Supplementary Materials 5.

Figure 3: *Individual network small-world differences between pre-ASM and post-ASM. For clarity, participants are spread across the x-axis if they display similar values.*

Discussion

We observed brain network changes after people commenced ASM treatment, reflecting increased network clustering and efficiency (Figure 1) and subsequent increase in network small-worldness (i.e., more efficient network function) following ASM treatment (Figure 3). These findings suggest that ASM may normalise functional brain networks. A loss of network small-worldness is associated with altered network topology during seizures [1] and is observed generally in epilepsy [11]. Increased network small-worldness has also been observed after successful epilepsy surgery [12], suggesting that small-world network topology is associated with a shift toward normal brain function following the introduction of medication.

After ASM treatment, the brain areas with the greatest network changes were those involved in cognitive function, such as working memory and language (Figure 2). Relatedly, an increased fMRI signal in the frontoparietal during a working memory task is correlated with valproate dosage [13], and precuneus activity was associated with ASM dosage in a verbal fluency task [14]. A potential mechanism for network changes post-ASM is that the brain functions sub-optimally before a person experiences a first seizure, as approximately half of new-onset epilepsy patients show impairment in attention, executive functions and memory [15]. ASM may restore normal function by reducing seizures or as a consequence of restoring network function.

Although the primary goal of our study was to quantify brain network changes after commencing ASM, a limitation of our work is how our results relate to different types of epilepsy and treatment responses. We acknowledge that it is unlikely that the only thing happening between the two scans is the addition of ASM. To further understand the relationship between brain network changes and seizure state, epilepsy diagnosis, and ASM requires larger studies. Another limitation of this study is that we did have longitudinal data from healthy controls. Future studies may benefit from including control populations to compare the effects of different types of medication over time on people without a seizure history.

Our network findings may also be helpful for disorders beyond epilepsy to monitor brain changes in neurological and psychiatric disorders where pharmacological interventions are used.

References

1. Pardoe HR, Berg AT, Jackson GD. Sodium valproate use is associated with reduced parietal lobe thickness and brain volume. Neurology. 2013;80:1895–1900.

2. Xiao F, Caciagli L, Wandschneider B, et al. Effects of carbamazepine and lamotrigine on functional magnetic resonance imaging cognitive networks. Epilepsia. 2018;59:1362–1371.

3. Wandschneider B, Stretton J, Sidhu M, et al. Levetiracetam reduces abnormal network activations in temporal lobe epilepsy. Neurology. 2014;83:1508–1512.

4. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319.

5. Spencer SS. Neural Networks in Human Epilepsy: Evidence of and Implications for Treatment. Epilepsia. 2002;43:219–227.

6. Esteban O, Markiewicz CJ, Blair RW, et al. fMRIPrep: a robust preprocessing pipeline for functional MRI. Nature Methods. Nature Publishing Group; 2019;16:111–116.

7. Glasser MF, Coalson TS, Robinson EC, et al. A multi-modal parcellation of human cerebral cortex. Nature. Nature Publishing Group; 2016;536:171–178.

8. Watts DJ, Strogatz SH. Collective dynamics of 'small-world' networks. Nature. 1998;393:440–442.

9. Pedersen M, Omidvarnia A, Shine JM, Jackson GD, Zalesky A. Reducing the influence of intramodular connectivity in participation coefficient. Netw Neurosci. 2020;4:416–431.

10. Kramer MA, Eden UT, Kolaczyk ED, Zepeda R, Eskandar EN, Cash SS. Coalescence and Fragmentation of Cortical Networks during Focal Seizures. J Neurosci. 2010;30:10076–10085.

11. Larivière S, Royer J, Rodríguez-Cruces R, et al. Structural network alterations in focal and generalized epilepsy assessed in a worldwide ENIGMA study follow axes of epilepsy risk gene expression. Nat Commun. Nature Publishing Group; 2022;13:4320.

12. Jackson GD, Pedersen M, Harvey AS. How small can the epileptogenic region be? A case in point. Neurology. 2017;88:2017–2019.

13. Vollmar C, O'Muircheartaigh J, Barker GJ, et al. Motor system hyperconnectivity in juvenile myoclonic epilepsy: a cognitive functional magnetic resonance imaging study. Brain. 2011;134:1710–1719.

14. Yasuda CL, Centeno M, Vollmar C, et al. The effect of topiramate on cognitive fMRI. Epilepsy Research. 2013;105:250–255.

15. Witt J-A, Helmstaedter C. Should cognition be screened in new-onset epilepsies? A study in 247 untreated patients. J Neurol. 2012;259:1727–1731.